Drug intelligence / Profile preview

lactulose + linaclotide

Development stage: Discontinued
Lead developer: Ironwood Pharmaceuticals
Modality: Small Molecules
Administration: Oral

Overview

A combination of two laxative medications that work through different mechanisms. Lactulose is a synthetic disaccharide that is broken down in the colon into products that pull water into the colon, softening stools. Linaclotide is a guanylate cyclase-C receptor agonist that stimulates intestinal fluid secretion by promoting chloride and bicarbonate efflux into the intestinal lumen through activation of the cystic fibrosis transmembrane conductance regulator.

Targets

GUCY2C (Guanylate cyclase C receptor)

Beyond the preview

Go deeper on lactulose + linaclotide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on lactulose + linaclotide.

Explore the full profile